[1]葛静,滑芳,冯艳萍.红藤方加减治疗卵巢型子宫内膜异位症74例临床观察[J].西部中医药,2020,33(04):34-38.[doi:10.12174/j.issn.1004-6852.2020.04.11]
　GE Jing,HUA Fang,FENG Yanping.Clinical Observation on Modified Hongteng Prescription in the Treatment of 74 Cases of Ovarian Endometriosis[J].Western Journal of Traditional Chinese Medicine,2020,33(04):34-38.[doi:10.12174/j.issn.1004-6852.2020.04.11]
点击复制

红藤方加减治疗卵巢型子宫内膜异位症74例临床观察
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
33
期数:
2020年04期
页码:
34-38
栏目:
出版日期:
2020-04-15

文章信息/Info

Title:
Clinical Observation on Modified Hongteng Prescription in the Treatment of 74 Cases of Ovarian Endometriosis
文章编号:
1004-6852(2020)04-0034-05
作者:
葛静，滑芳，冯艳萍
河北医科大学第一医院，河北 石家庄 050031
Author(s):
GE Jing, HUA Fang △, FENG Yanping
The First Hospital of Hebei Medical University, Shijiazhuang 050031, China
关键词:
子宫内膜异位症; 卵巢型; 红藤方加减; 血清激素; 糖链抗原125; 基质金属蛋白酶9
Keywords:
endometriosis;  ovarian;  modified Hongteng prescription;  serum hormone;  CA125;  MMP-9
分类号:
R285
DOI:
10.12174/j.issn.1004-6852.2020.04.11
文献标志码:
A
摘要:
目的：探讨红藤方加减对卵巢型子宫内膜异位症(endometriosis，EM)患者的疗效及对血清激素、糖链抗原125(carbohydrate antigen125，CA125)及基质金属蛋白酶9(Matrix Metalloproteinase 9， MMP-9)表达水平的影响。方法：将147例患者按随机数字表法分为观察组(74例)、对照组(73例)。两组患者均行腹腔镜保守手术治疗。给予对照组患者注射用醋酸亮丙瑞林微球(商用名：抑那通)治疗，观察组在此基础上被给予红藤方加减，两组患者均进行3个月经周期的治疗，结束后对两组患者临床疗效、血清激素、CA125、组织金属蛋白酶抑制剂1(Tissue inhibitor of metalloproteinase-1，TIMP-1)与MMP-9及血液流变学指标进行比较。结果：总有效率观察组为93.24%(69/74)，对照组为80.82%(59/73)，两组比较差异有统计学意义(P＜0.05)。异位囊肿最大截面积、痛经症状积分治疗前两组比较，差异无统计学意义(P＞0.05)；治疗前后两组组内比较，差异有统计学意义(P＜0.05)；治疗后两组组间比较，差异有统计学意义(P＜0.05)。血清雌二醇(estradiol，E2)、黄体生成素(luteinizing hormone，LH)、促卵泡生成素(follicle-stimulating Hormone，FSH)、CA125、MMP-9、TIMP-1及MMP-9/TIMP-1水平治疗前两组比较，差异无统计学意义(P＞0.05)；治疗前后两组组内比较，治疗后两组组间比较，差异均有统计学意义(P＜0.05)。全血高、低切黏度，红细胞聚集指数及红细胞压积治疗前两组比较，差异无统计学意义(P＞0.05)；治疗前后两组组内比较，差异有统计学意义(P＜0.05)；治疗后两组组间比较，差异有统计学意义(P＜0.05)。两组治疗过程中不良反应轻微，经对症处理后消失。结论：红藤方加减对卵巢型EM患者具有积极的治疗效果，可改善患者血清激素与CA125及MMP-9水平，调节血液流变学指标，有效改善临床症状。
Abstract:
Objective: To discuss clinical efficacy of modified Hongteng prescription in the treatment of the patients with ovarian endometriosis (EM) and its effects on the expressions of serum hormone, CA125 and MMP-9. Methods: All 147 patients were separated into the observation group (74 cases) and the control group (73 cases). Both groups accepted laparoscopic conservative surgery. The patients in the control group were treated by enantone, and the ones in the observation group by modified Hongteng prescription, both groups were treated for three menstrual cycles, by the end of the therapy, to compare clinical effects, serum hormone, CA125, TIMP-1, MMP-9 and hemorheological indexes between both groups. Results: Total effective rate of the observation group was 93.24%(67/74), higher than 80.82%(59/73) of the control group, and the difference had statistical meaning (P＜0.05). The difference had no statistical meaning in maximum cross-sectional area of heterotopic cyst and dysmenorrhea symptom score before treating between both groups (P＞0.05); the difference had statistical meaning between both groups before and after treating (P＜0.05); the difference was statistically significant between both groups after treating (P＜0.05). The difference had no statistical meaning in the levels of E2, LH, FSH, CA125, MMP-9, TIMP-1 and MMP-9/TIMP-1 before treating (P＞0.05); the difference presented statistical meaning within two groups before and after treating (P＜0.05); the difference presented statistical meaning between two groups after treating (P＜0.05). The difference had no statistical meaning in the comparisons of high and low shear viscosity of whole blood, erythrocyte aggregation index and hematocrit between both groups before treating (P＞0.05); the difference presented statistical meaning within two groups before and after treating (P＜0.05); the difference presented statistical meaning between two groups after treating (P＜0.05). Adverse reaction was slight during therapeutic course and disappeared after symptomatic treatment. Conclusion: Modified Hongteng prescription possess the positive therapeutic effects in the treatment of the patients with ovarian EM, it could raise the expressions of serum hormone, CA125 and MMP-9, regulate hemorheological indexes and effectively improve clinical symptoms.

相似文献/References:

[1]王颖.辨证论治子宫内膜异位症118例[J].西部中医药,2013,26(12):85.
　WANG Ying.Syndrome Differentiation and Treatment for 118 Cases of Endometriosis[J].Western Journal of Traditional Chinese Medicine,2013,26(04):85.
[2]葛慧娟,曹保利.子宫内膜异位症术后应用复方莪术散的疗效观察[J].西部中医药,2014,27(04):100.
　GE Huijuan,CAO Baoli.Clinical Observation on Compound EZhu Powder Applied to the Patients after the Surgery of Endometriosis[J].Western Journal of Traditional Chinese Medicine,2014,27(04):100.
[3]李红霞,万国蕊,徐静,等.三花益肾汤治疗子宫内膜异位症临床观察[J].西部中医药,2015,28(01):7.
[4]陆建英,董莉,谭蕾,等.朱南孙治疗子宫内膜异位症经验举隅*[J].西部中医药,2013,26(10):42.
　LU Jianying,DONG Li,TAN Lei,et al.Examples of Zhu Nansun Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2013,26(04):42.
[5]董迹菲,翟培杞,孙炜,等.基于数据挖掘的针灸治疗子宫内膜异位症选穴配伍规律的文献研究[J].西部中医药,2015,28(06):86.[doi:2015/6/16 0:00:00]
[6]胡淑寒,曹保利△,刘霞,等.中药治疗子宫内膜异位症的用药规律研究[J].西部中医药,2018,31(09):87.
　HU Shuhan,CAO Baoli,LIU Xia,et al.Drug Use Law of Traditional Chinese Medicine in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2018,31(04):87.
[7]唐晓琳,石璇△.中药治疗子宫内膜异位症的临床效果[J].西部中医药,2017,30(01):66.
　TANG Xiaolin,SHI Xuan.Clinical Effects of Chinese Materia Medica in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2017,30(04):66.
[8]刘帅,曹保利.莪术油对大鼠子宫内膜异位症基质细胞衍生因子-1及其受体表达的影响[J].西部中医药,2018,31(03):26.
　LIU Shuai,CAO Baoli.The Effects of Curcuma Zedoary Oil on the Expressions of Stromal Cell Derived Factor-1 and Its Receptor in Endometriosis Rats Model[J].Western Journal of Traditional Chinese Medicine,2018,31(04):26.
[9]徐群群,卢敏,曹阳,等.清热化瘀法对子宫内膜异位症患者血管生成机制的影响[J].西部中医药,2019,32(02):1.
　XU Qunqun,LU Min,CAO Yang,et al.The Effects of Heat-clearing Stasis-eliminating Method on the Mechanism of Angiogenesis of Endometriosis Patients[J].Western Journal of Traditional Chinese Medicine,2019,32(04):1.
[10]张彩凤.益肾汤联合孕三烯酮治疗子宫内膜异位症[J].西部中医药,2019,32(03):87.
　ZHANG Caifeng.Kidney-nourishing Decoction Combined with Gestrinone in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2019,32(04):87.
[11]李晨阳,张学红.人参皂苷Rg3通过PI3K/Akt信号通路抑制大鼠卵巢型子宫内膜异位症血管生成相关因子表达机制研究[J].西部中医药,2022,35(11):66.[doi:10.12174/j.issn.2096-9600.2022.11.12]
　LI Chenyang,ZHANG Xuehong.Study on the Mechanism of Inhibiting Angiogenesis-related Factors Expression in Ovarian Endometriosis Rats by Ginsenoside Rg3 via P13K/Akt Signaling Pathway[J].Western Journal of Traditional Chinese Medicine,2022,35(04):66.[doi:10.12174/j.issn.2096-9600.2022.11.12]

备注/Memo

备注/Memo:
收稿日期：2019-06-13*基金项目：河北省2015年度医学科学重点课题计划项目（20150204）。作者简介：葛静(1977—)，女，副主任医师。研究方向：妇科疾病的基础与临床研究。△通讯作者：滑芳(1972—)，女，主任医师。研究方向：妇科肿瘤的研究。
更新日期/Last Update: 2020-04-15